Treventis attends RESI Nov 2021

Treventis CEO Christopher Barden attended the second of the fall Redefining Early Stage Investments (RESI) conferences (held virtually this year due to COVID-19). This conference is a prominent event for life sciences and medical technology companies looking to raise funds for the next stage of their company development. Treventis was proud to schedule meetings with over a dozen investors and organizations with interest in neurodegenerative and oncology drug development.